Dr. Kaushik Deb: Laying Foundation For A Refurbished Bio-Pharma Sector
Dr. Kaushik Deb
Founder & MD
Below is an excerpt of Dr. Kaushik's interview with CEO Insights.
What inspired you to start your entrepreneurial journey in this segment of Health Care and what drives you today as an entrepreneur?
Researching deeper into how new pharma drugs are developed and clinical trials are designed to get a desirable outcome, I realized the
the age old adage Prevention is better than cure and that a personalized approach in prescription can lead treatments to cure! And thus we embarked on Personalized and Precision Medicine!
Since every patient responds to a drug differently and not all patients need the same dosage, with more than 20k drugs in the whole world, a physician can't know or analyze adverse effects due to drug drug interactions and drug overloads.
Apart from working towards finding solutions to such problems, we are also exploring a plethora of opportunities in telemedicine, bigdata, pharmacogenomics, metabolomics, metagenomics, artificial intelligence, and IoT, as the Pandemic has fast forwarded the healthcare world by at least 2 decades.
Putting your academic career at IIM Bangalore into words share some of your unique experiences?
Although I always had a desire to give wings to my thoughts; I think the IIM environment fired the entrepreneurial instinct. Going through numerous group activities, group exercises, assignments, and homework exposed me to teamwork along with various industry verticals such as marketing economics sales, HR, accounting, and so on. Every lecture kept me thoroughly engaged and I was very much influenced by the intelligent fellow students I had in my batch.
How would you define Diponed Biointelligence as an organization and its position in the market?
Creating a niche market in health
Although I always had a desire to give wings to my thoughts; I think the IIM environment fired the entrepreneurial instinct
Since every patient responds to a drug differently and not all patients need the same dosage, with more than 20k drugs in the whole world, a physician can't know or analyze adverse effects due to drug drug interactions and drug overloads.
Apart from working towards finding solutions to such problems, we are also exploring a plethora of opportunities in telemedicine, bigdata, pharmacogenomics, metabolomics, metagenomics, artificial intelligence, and IoT, as the Pandemic has fast forwarded the healthcare world by at least 2 decades.Putting your academic career at IIM Bangalore into words share some of your unique experiences?
Although I always had a desire to give wings to my thoughts; I think the IIM environment fired the entrepreneurial instinct. Going through numerous group activities, group exercises, assignments, and homework exposed me to teamwork along with various industry verticals such as marketing economics sales, HR, accounting, and so on. Every lecture kept me thoroughly engaged and I was very much influenced by the intelligent fellow students I had in my batch.
How would you define Diponed Biointelligence as an organization and its position in the market?
Creating a niche market in health
care, especially across personalized biologicals and devices production, we are currently going through US FDA approvals and have signed up for distributions in various countries like the USA, Canada, African countries, UAE, and more. Besides this, we have more than five new age cellular therapies in research and development for unmet health care needs which are unique in terms of global availability. We have partnered with several hospitals all over India to offer our molecular diagnostics/tests that are related to personalized medicine.
Since India has largely been focusing on generics production, there is a gap in the understanding of the Preclinical stage/assays of Drug development. Leveraging our extremely talented scientific team, we have also developed a Pharma Contract Research Services division in a short span across the pre clinical drug development and servicing large pharma to Startups that are involved in drug discovery.
How would you describe your role in tackling the COVID-imposed challenges?
Although Covid has presented some challenges indeed in our marketing strategies as meeting doctors became restricted, we have adopted digital education and are trying to increase our digital presence. Covid made us realize that we could switch some of our business to D2C from the current B2B, for faster growth. We have taken our coupled tests and the therapeutic products directly to the customers(D2C) through digital/social media platforms.
Dr. Kaushik Deb,Founder & MD, Diponed Biointelligence
Dr. Kaushik's interest to work on disrupting technologies that would change the current health care systems and transform ‘Treatments to Cure' enabled him to establish Diponed Biointelligence
Since India has largely been focusing on generics production, there is a gap in the understanding of the Preclinical stage/assays of Drug development. Leveraging our extremely talented scientific team, we have also developed a Pharma Contract Research Services division in a short span across the pre clinical drug development and servicing large pharma to Startups that are involved in drug discovery.
How would you describe your role in tackling the COVID-imposed challenges?
Although Covid has presented some challenges indeed in our marketing strategies as meeting doctors became restricted, we have adopted digital education and are trying to increase our digital presence. Covid made us realize that we could switch some of our business to D2C from the current B2B, for faster growth. We have taken our coupled tests and the therapeutic products directly to the customers(D2C) through digital/social media platforms.
Dr. Kaushik Deb,Founder & MD, Diponed Biointelligence
Dr. Kaushik's interest to work on disrupting technologies that would change the current health care systems and transform ‘Treatments to Cure' enabled him to establish Diponed Biointelligence